North America Cell and Gene Therapy Manufacturing QC Market Size, Share & Trends Analysis Report By Therapy Type (Cell Therapy, Gene Therapy), By Scale (Pre-Commercial/R&D Manufacturing, Commercial Scale Manufacturing), By Mode (Contract Manufacturing, In-House Manufacturing), By Workflow (Cell Processing, Cell Banking, Fill & Finish Operations, Vector Production, Others), By Process (Upstream Processes, Downstream Processes), By End User (Pharmaceutical Companies, Contract Manufacturing Organizations), By Technology Type (Fluorescence-Activated Cell Sorting, Next-Generation Sequencing), By Country (U.S., Canada), Forecasts, 2026-2034

North America Cell and Gene Therapy Manufacturing QC Market Size

The North America Cell and Gene Therapy Manufacturing QC Market size was valued at USD 1.20 billion in 2025 and is projected to grow from USD 1.42 billion in 2026 to USD 5.29 billion by 2034 at a CAGR of 17.92% during the forecast period 2026–2034.

This market is experiencing rapid growth, driven by the increasing number of clinical trials and rising investments in advanced therapies. Additionally, the market is projected to witness significant growth due to the presence of cutting-edge biopharmaceutical companies and a well-established regulatory framework in North America.

Type Insights

Cell Therapy dominates the therapy type segment and is estimated to grow at a CAGR of 23.3%. This segment is growing rapidly in the North America Cell and Gene Therapy Manufacturing QC Market due to the increasing number of clinical applications, particularly in cancer treatment. Therapies like CAR-T are gaining approval, driving demand for stringent QC processes to ensure safety, efficacy, and regulatory compliance.

Request Customizationto receive a tailored report.

Scale Insights

Pre-commercial/ R&D Manufacturing is estimated to own the scale segment and is anticipated to expand at a CAGR of 24.8%. The pre-commercial/R&D manufacturing segment is expanding due to the increasing number of early-stage clinical trials for cell and gene therapies. Companies are investing in QC to meet regulatory standards during initial phases, ensuring product safety and efficacy, which is crucial for progressing to later clinical stages and eventual commercialization.

Mode Insights

In-house manufacturing dominates the mode segment and is expected to augment at a CAGR of 24.8%. In-house manufacturing is growing as biopharmaceutical companies seek greater control over production quality and regulatory compliance in cell and gene therapies. By establishing dedicated QC facilities, companies can streamline processes, reduce reliance on third-party manufacturers, and ensure more efficient oversight of product consistency and safety.

Workflow Insights

Vector Production dominates the workflow segment and is expected to augment at a CAGR of 26.4%. The vector production workflow segment is expanding as viral vectors, such as lentivirus and AAV, are critical for delivering gene therapies. Demand for efficient QC in vector production is rising due to the need to ensure purity, potency, and scalability, especially as gene therapy pipelines grow and regulatory scrutiny intensifies.

Speak to an Analystto discuss market opportunities.

Country Insights

The North American region, dominated by the United States, is the leading area for this industry. The U.S. holds the largest market share, driven by the advanced healthcare infrastructure and strong regulatory frameworks. Several factors contribute to the U.S. leadership in this space. The FDA's proactive regulatory approach, through initiatives like the "Breakthrough Therapy Designation," fast-tracks the approval of innovative therapies while ensuring rigorous QC standards are met. In 2022, the FDA approved 18 gene therapy investigational new drug (IND) applications, underscoring the critical role of stringent QC in the approval process.

Additionally, major biopharmaceutical companies, including Novartis, Pfizer, and Gilead, have established advanced QC laboratories in the U.S. to support their cell and gene therapy production facilities. These facilities are equipped with cutting-edge QC tools like Next-Generation Sequencing (NGS) and digital PCR, ensuring precise monitoring of product safety and efficacy. Novartis, for instance, invested $500 million in 2022 to expand its gene therapy manufacturing capabilities in North Carolina, which includes QC infrastructure development.

Furthermore, the key players in this market are introducing novel products in this segment to enhance their market share.

• For instance, in March 2024, Slingshot Bio launched a range of solutions to address quality control issues in cell therapy development and manufacturing.

These controls are essential for validating the accuracy and consistency of analytical procedures employed to assess cell therapy products. Thus, such factors are estimated to augment the regional market growth.

List of Key and Emerging Players in North America Cell and Gene Therapy Manufacturing QC Market